BRIXADI (buprenorphine) extended-release injection for subcutaneous use contains a medicine called buprenorphine. Buprenorphine is an opioid that can cause serious and life-threatening breathing …

Mar 22, 2026 · Brixadi is an extended-release injection of buprenorphine given by a healthcare provider that may be used to treat moderate to severe opioid use disorder (OUD) (also known as opioid …

Today, the U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (under the skin) to treat moderate to severe opioid use disorder...

BRIXADI is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already …

Find answers to your questions about how FDA-approved BRIXADI works, including starting and staying on treatment. Please see Prescribing Information, including Boxed Warning, and Medication Guide.

BRIXADI is the ONLY injectable buprenorphine that offers multiple monthly and weekly dosing options. Patients currently on transmucosal buprenorphine treatment can be switched directly to BRIXADI …

Dec 16, 2024 · Find patient medical information for Brixadi (buprenorphine) on WebMD including its uses, side effects and safety, interactions, pictures, warnings, and user ratings